Literature DB >> 27819485

Pilot Randomized Controlled Trial of Omega-3 and Individual-Family Psychoeducational Psychotherapy for Children and Adolescents With Depression.

Mary A Fristad1, Anthony T Vesco1, Andrea S Young1, K Zachary Healy1, Elias S Nader1, William Gardner1, Adina M Seidenfeld1, Hannah L Wolfson1, L Eugene Arnold1.   

Abstract

The goal of this study is to evaluate feasibility and estimate effect sizes of omega-3 fatty acids (Ω3), individual-family psychoeducational psychotherapy (PEP), their combination, and moderating effects of maternal depression and psychosocial stressors in youth with depression. In a pilot 2 × 2 randomized controlled trial, 72 youth (ages 7-14; 57% Caucasian, 57% male) with major depression, dysthymia, or depression not otherwise specified were randomized to 12 weeks of Ω3, PEP+placebo, Ω3+PEP, or placebo. Ω3 versus placebo was double-masked. Evaluators masked to condition assessed depressive severity at baseline (randomization) and at 2, 4, 6, 9, and 12 weeks using the Children's Depression Rating Scale-Revised. Side effects were either absent or mild. PEP was administered with 74% fidelity. Remission was 77%, Ω3+PEP; 61%, PEP+placebo; 44%, Ω3; 56%, placebo. Intent-to-treat analyses found small to medium effects of combined treatment (d = .29) and Ω3 monotherapy (d = .42), but negligible effect for PEP+placebo (d < .10), all compared to placebo alone. Relative to placebo, youth with fewer social stressors responded better to Ω3 (p = .04), PEP (p = .028), and their combination (p = .035), and those with maternal depression responded better to PEP (p = .020) than did those without maternal depression. Remission rates were favorable compared to other studies of psychotherapy and comparable to an existing randomized controlled trial of Ω3; results warrant further evaluation in a larger sample. Ω3 was well tolerated. Active treatments show significantly more placebo-controlled depression improvement in the context of maternal depression and fewer stressors, suggesting that they may benefit depression with a more endogenous than environmental origin.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27819485      PMCID: PMC6066443          DOI: 10.1080/15374416.2016.1233500

Source DB:  PubMed          Journal:  J Clin Child Adolesc Psychol        ISSN: 1537-4416


  53 in total

1.  Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) mania and rapid cycling sections.

Authors:  B Geller; B Zimerman; M Williams; K Bolhofner; J L Craney; M P DelBello; C Soutullo
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-04       Impact factor: 8.829

2.  Study IV: concurrent validity of the DSM-IV revised Children's Interview for Psychiatric Syndromes (ChIPS).

Authors:  M A Fristad; J Cummins; J S Verducci; M Teare; E B Weller; R A Weller
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

3.  Study V: Children's Interview for Psychiatric Syndromes (ChIPS): psychometrics in two community samples.

Authors:  M A Fristad; A R Glickman; J S Verducci; M Teare; E B Weller; R A Weller
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

4.  Brief screening for family psychiatric history: the family history screen.

Authors:  M M Weissman; P Wickramaratne; P Adams; S Wolk; H Verdeli; M Olfson
Journal:  Arch Gen Psychiatry       Date:  2000-07

5.  Subthreshold depression in adolescence and mental health outcomes in adulthood.

Authors:  David M Fergusson; L John Horwood; Elizabeth M Ridder; Annette L Beautrais
Journal:  Arch Gen Psychiatry       Date:  2005-01

6.  Omega-3 treatment of childhood depression: a controlled, double-blind pilot study.

Authors:  Hanah Nemets; Boris Nemets; Alan Apter; Ziva Bracha; R H Belmaker
Journal:  Am J Psychiatry       Date:  2006-06       Impact factor: 18.112

Review 7.  Course and outcome of child and adolescent major depressive disorder.

Authors:  Boris Birmaher; Clara Arbelaez; David Brent
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2002-07

8.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

9.  Family discord and stress predictors of depression and other disorders in adolescent children of depressed and nondepressed women.

Authors:  Constance Hammen; Patricia A Brennan; Josephine H Shih
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-08       Impact factor: 8.829

10.  Cross-national comparisons of seafood consumption and rates of bipolar disorders.

Authors:  Simona Noaghiul; Joseph R Hibbeln
Journal:  Am J Psychiatry       Date:  2003-12       Impact factor: 18.112

View more
  14 in total

1.  Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies.

Authors:  L Eugene Arnold; Andrea S Young; Martha A Belury; Rachel M Cole; Barbara Gracious; Adina M Seidenfeld; Hannah Wolfson; Mary A Fristad
Journal:  J Child Adolesc Psychopharmacol       Date:  2017-02-03       Impact factor: 2.576

2.  Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.

Authors:  Robert K McNamara; Jeffrey R Strawn; Max J Tallman; Jeffrey A Welge; L Rodrigo Patino; Thomas J Blom; Melissa P DelBello
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-03-11       Impact factor: 2.576

3.  Psychoeducational Psychotherapy and Omega-3 Supplementation Improve Co-Occurring Behavioral Problems in Youth with Depression: Results from a Pilot RCT.

Authors:  Andrea S Young; L Eugene Arnold; Hannah L Wolfson; Mary A Fristad
Journal:  J Abnorm Child Psychol       Date:  2017-07

4.  Predicting enrollment in two randomized controlled trials of nonpharmacologic interventions for youth with primary mood disorders.

Authors:  Andrea S Young; Adina M Seidenfeld; K Zachary Healy; L Eugene Arnold; Mary A Fristad
Journal:  J Affect Disord       Date:  2018-04-04       Impact factor: 4.839

5.  Omega-3 supplementation associated with improved parent-rated executive function in youth with mood disorders: secondary analyses of the omega 3 and therapy (OATS) trials.

Authors:  Anthony T Vesco; Andrea S Young; L Eugene Arnold; Mary A Fristad
Journal:  J Child Psychol Psychiatry       Date:  2017-10-24       Impact factor: 8.982

Review 6.  Management of Emotion Dysregulation and Outbursts in Children and Adolescents.

Authors:  Michael Sorter; Jaclyn Chua; Martine Lamy; Drew Barzman; Louis Ryes; Joshua Abraham Shekhtman
Journal:  Curr Psychiatry Rep       Date:  2022-03-22       Impact factor: 5.285

7.  Is evidence-based treatment helping my patient? Utilizing modified Brinley plots to measure clinical change.

Authors:  Sarah R Black; Neville Blampied; L Eugene Arnold; Mary A Fristad
Journal:  Clin Psychol (New York)       Date:  2018-12-28

8.  Moody kids years later: Long-term outcomes of youth from the Omega-3 and therapy (OATS) studies.

Authors:  Mary A Fristad; Michelle E Roley-Roberts; Sarah R Black; L Eugene Arnold
Journal:  J Affect Disord       Date:  2020-11-27       Impact factor: 4.839

Review 9.  Disentangling the Molecular Mechanisms of the Antidepressant Activity of Omega-3 Polyunsaturated Fatty Acid: A Comprehensive Review of the Literature.

Authors:  Hans O Kalkman; Martin Hersberger; Suzanne Walitza; Gregor E Berger
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

10.  Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial.

Authors:  Lisa M Christian; Andrea S Young; Amanda M Mitchell; Martha A Belury; Barbara L Gracious; L Eugene Arnold; Mary A Fristad
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.